How to Test for Carcinoid Syndrome: Urine, Blood & Imaging

Testing for carcinoid syndrome typically begins with a urine or blood test that measures a chemical called 5-HIAA, a breakdown product of serotonin, because most carcinoid tumors overproduce serotonin. But the full workup rarely stops at a single test. Depending on results, doctors layer in additional blood markers, specialized nuclear-medicine scans that light up tumor cells, conventional imaging to map the anatomy, and sometimes cardiac screening. Each test answers a different question, and understanding what they measure and where they fall short helps you prepare for the process.

What Carcinoid Syndrome Actually Is

Carcinoid syndrome is not a cancer diagnosis in itself. It is a collection of symptoms caused by hormones and other substances that certain neuroendocrine tumors release into the bloodstream. The hallmark symptoms are flushing (sudden redness and warmth, usually in the face and upper body), watery diarrhea, wheezing, and sometimes heart valve problems. Roughly 30 to 40 percent of people with well-differentiated neuroendocrine tumors develop the syndrome.¹ Most of these tumors originate in the small intestine, though they can arise in the lungs, stomach, or elsewhere. When a small bowel tumor has already spread to the liver, its hormonal products bypass the liver’s filtering and flood the general circulation, which is typically what triggers symptoms.

Because the symptoms can mimic many other conditions, from irritable bowel syndrome to menopause-related hot flashes, laboratory confirmation matters. A review of flushing disorders noted that serious diagnoses such as carcinoid syndrome, pheochromocytoma, and mastocytosis need to be specifically excluded through lab and imaging studies when the clinical picture is unclear. Testing is how you move from suspicion to certainty.

The 24-Hour Urine 5-HIAA Test

The longest-standing biochemical test for carcinoid syndrome is the 24-hour urine collection for 5-hydroxyindoleacetic acid (5-HIAA). Your body converts serotonin into 5-HIAA and excretes it in urine, so an abnormally high level signals that serotonin production is ramped up. Overall, published sensitivity and specificity for this test in people with carcinoid syndrome are in the neighborhood of 70 percent and 90 percent, respectively, though exact numbers shift depending on the cutoff the lab uses.² A more recent single-center study reported a sensitivity of 100 percent at a cutoff of 50 µmol per 24 hours, with specificity around 69 percent; raising the cutoff improved specificity at the cost of catching fewer cases.³

The practical downside is that you have to collect every drop of urine over a full 24-hour period in a special container, keep it refrigerated, and then deliver it to the lab. That is inconvenient enough that many patients do it incorrectly, which muddies results.

Foods and Drugs That Cause False Positives

Certain foods naturally contain serotonin or its precursor tryptophan, and eating them shortly before or during the collection can push your 5-HIAA reading above the normal range even if you have no tumor. Known offenders include bananas, pineapples, kiwis, plums, avocados, walnuts, eggplant, and tomatoes.⁴ Medications and supplements such as acetaminophen, nicotine, and caffeine can also interfere. Most guidelines recommend avoiding these substances for at least 24 to 72 hours before starting the urine collection.⁴ If you get an unexpectedly high result, your doctor may ask you to repeat the test after a stricter dietary restriction period before pursuing more invasive workup.

Blood-Based 5-HIAA as an Alternative

Because the 24-hour urine collection is cumbersome, there has been growing interest in measuring 5-HIAA directly from a blood draw. The evidence is encouraging. One study found that plasma and urine 5-HIAA had very similar diagnostic accuracy, with areas under the curve of 0.917 and 0.920, respectively, meaning neither had a clear edge over the other.⁵ Another study using a streamlined lab method confirmed that a serum 5-HIAA assay performed as well as the 24-hour urine version in distinguishing active disease from remission.⁶ A separate investigation showed that plasma and serum samples can be used interchangeably, with significant statistical agreement against the urine reference standard.⁷

Blood-based testing is not yet universally available, and many labs still default to the urine collection. But where it is offered, a single blood draw is far simpler and eliminates most of the collection errors that plague the urine method. The same dietary precautions apply, though. Serotonin-containing foods can raise blood 5-HIAA within two hours of eating, and the spike can take up to a full day to clear.⁸ So whether your test is urine or blood, you need to watch what you eat beforehand.

Chromogranin A and Its Limitations

Beyond 5-HIAA, doctors often order a blood test for chromogranin A (CgA), a protein released by neuroendocrine cells. CgA is considered the most widely used general biomarker for neuroendocrine tumors, and its levels tend to reflect overall tumor burden.⁹ It is less specific to carcinoid syndrome than 5-HIAA because it does not measure serotonin activity. Instead, think of it as a flag that neuroendocrine cells are active somewhere in the body.

The biggest pitfall with CgA is the list of other things that elevate it. Proton pump inhibitors (PPIs), the acid-blocking drugs millions of people take for heartburn, are the single most common non-tumor cause of elevated CgA.¹⁰ Chronic kidney disease, heart failure, high blood pressure, and even hypothyroidism can also push the number up.¹¹ If you are on a PPI, your doctor will typically ask you to stop it, usually for at least two weeks, before drawing CgA. Otherwise the result is nearly uninterpretable.

Monitoring for Carcinoid Heart Disease

One of the most serious complications of carcinoid syndrome is damage to the heart valves, especially the tricuspid and pulmonary valves on the right side of the heart. Serotonin is thought to drive a fibrotic thickening of these valves, eventually causing them to leak or stiffen. Echocardiography, a standard ultrasound of the heart, is the primary tool for detecting and grading this damage.¹² Most guidelines recommend a baseline echocardiogram at the time of carcinoid syndrome diagnosis, with repeat studies at regular intervals even if the first one is normal, because valve disease can develop gradually.

A blood marker called NT-proBNP, widely used in general cardiology to assess heart strain, turns out to be a useful screening complement. A cross-sectional study found that NT-proBNP had the highest accuracy for predicting the presence of carcinoid heart disease among a panel of biomarkers tested, with an area under the curve of 0.82. Plasma 5-HIAA performed similarly, at 0.85, while chromogranin A was not meaningfully correlated with heart valve severity.¹³ In practical terms, if both your 5-HIAA and NT-proBNP are elevated, your medical team will be especially attentive to heart valve surveillance.

Somatostatin Receptor Imaging

Once biochemical tests suggest a neuroendocrine tumor, the next step is usually imaging to find and map it. The current gold standard for functional imaging is a PET/CT scan using gallium-68 DOTATATE, a radioactive tracer that binds to somatostatin receptors on the surface of most well-differentiated neuroendocrine tumor cells.¹⁴ The scan lights up wherever those receptors are concentrated, giving doctors a whole-body picture of tumor locations.

This technology replaced an older scan called octreotide scintigraphy (sometimes called an OctreoScan), which used a different radiotracer and a gamma camera. Head-to-head comparisons consistently show that gallium-68 DOTATATE PET/CT detects more lesions than the older scan, with the additional lesions often found in the liver or bowel.¹⁵ A systematic review and meta-analysis confirmed that gallium-68 DOTATATE is more sensitive overall and improves staging accuracy.¹⁶ If your center still offers only the older scan, it is worth asking whether a DOTATATE PET/CT is accessible, because the added resolution can change treatment decisions.

When FDG PET/CT Adds Value

The standard FDG PET/CT scan used in most cancer workups measures glucose metabolism, not somatostatin receptors. Slow-growing, well-differentiated neuroendocrine tumors tend not to consume much glucose, so FDG PET often misses them entirely. But higher-grade or dedifferentiated tumors flip the pattern: they may lose their somatostatin receptors while ramping up glucose consumption. In these cases, FDG PET/CT can outperform the DOTATATE scan and even outperform traditional tissue grading in predicting how aggressively the disease will behave.¹⁴ A positive FDG PET in a neuroendocrine tumor has been associated with more aggressive disease and less differentiated cells.¹⁷ Some centers now perform both scans together, a “dual-tracer” approach, to capture the full spectrum of tumor behavior. The role of FDG PET in clinical decision-making is still evolving, though its prognostic value is widely accepted.¹⁸

CT, MRI, and Endoscopy for Anatomical Detail

Functional scans show where tumor cells are metabolically active but can be vague about anatomy. Multiphasic CT scans with contrast fill that gap. Neuroendocrine liver metastases, for example, are often best seen during the arterial phase of a contrast-enhanced liver CT, when they light up brightly before the surrounding liver tissue enhances.¹⁹ MRI serves a complementary role. In clinical practice, most patients end up with at least one cross-sectional scan (CT or MRI) in addition to their functional scan, because surgeons need precise anatomical mapping before deciding whether resection is feasible.

Small bowel tumors present a special challenge because the jejunum and ileum are notoriously difficult to see with standard CT or colonoscopy. Video capsule endoscopy, in which you swallow a pill-sized camera that travels through the entire gut, has proven effective at finding primary tumors in the small bowel that other modalities miss. One case series found that capsule endoscopy detected small bowel tumors in about 83 percent of cases, compared with about 63 percent for CT and 21 percent for colonoscopy, and its findings correlated most closely with what surgeons actually found at operation.²⁰ Balloon-assisted enteroscopy, a more invasive endoscopic technique, allows both visualization and biopsy of lesions deep in the small bowel, and is particularly helpful for identifying multifocal disease, which can change the surgical plan.²¹

Tissue Biopsy and Pathology

Imaging and blood work can strongly suggest a neuroendocrine tumor, but the definitive diagnosis still comes from looking at tumor tissue under a microscope. A biopsy, whether taken during endoscopy, a CT-guided needle procedure, or surgery, undergoes immunohistochemistry staining. Pathologists check for markers like synaptophysin, chromogranin, and a newer marker called INSM1 to confirm that the cells are neuroendocrine in origin. They also measure a proliferation marker, Ki-67, which tells the grading story: a low Ki-67 means a slow-growing tumor, while a high Ki-67 suggests aggressive behavior. More advanced staining with lineage-restricted transcription factors can help pinpoint the organ of origin when someone presents with metastatic disease and the primary tumor cannot be located on scans.²² This matters because treatment strategies differ depending on where the tumor started.

How DOTATATE Scans Guide Treatment, Not Just Diagnosis

The gallium-68 DOTATATE PET/CT is not only a diagnostic tool. It plays a direct role in determining whether a patient is eligible for a targeted therapy called peptide receptor radionuclide therapy (PRRT), in which a therapeutic dose of radiation is attached to the same DOTATATE molecule and delivered intravenously. The tracer finds its way to tumor cells expressing somatostatin receptors, delivering radiation directly to them. But for PRRT to work, the tumor has to take up enough tracer. Baseline SUV, a measure of how avidly the tumor absorbs the radiotracer, correlates with somatostatin receptor density on the cell surface, and that receptor density in turn predicts treatment response.²³

Recent research has quantified this further. Patients with higher tumor uptake on the diagnostic scan tended to live longer after PRRT, while those with very high tumor volumes visible on the scan had worse overall survival.²⁴ There is a ceiling to the relationship between SUV and actual receptor density, meaning that extremely high tracer uptake does not always mean proportionally more receptors.²⁵ Still, the scan gives clinicians a reasonable window into whether PRRT is likely to help, making it one of the clearest examples of “theranostics” in oncology, where the same molecule diagnoses and treats.

When the Biochemistry Does Not Follow the Usual Pattern

Not every carcinoid tumor plays by the serotonin rules. A small subset of tumors, particularly those arising in the stomach, secrete a precursor called 5-hydroxytryptophan (5-HTP) rather than serotonin itself. These patients can have a distinctive flush pattern, elevated urinary histamine, and surprisingly normal platelet serotonin levels. Their urine 5-HIAA may be only mildly elevated or even normal, potentially leading to a missed diagnosis if the clinician relies on the standard 5-HIAA test alone. This “atypical carcinoid syndrome” was recognized decades ago and remains a clinical trap for the unwary.

Bronchial carcinoids can also behave differently, sometimes producing histamine or other substances that cause a more intense, prolonged flush. In any case where symptoms strongly suggest carcinoid syndrome but 5-HIAA comes back normal, the clinical team may pursue additional biochemical tests, serotonin receptor imaging, or a tissue biopsy rather than dismissing the diagnosis outright. The lesson for patients is that a single normal lab result does not always close the door.

Putting the Pieces Together in Practice

No single test tells the whole story. In practice, the workup for carcinoid syndrome follows a sequence driven by clinical suspicion. It usually starts with a 5-HIAA measurement, either urine or blood. If that is elevated and other causes have been excluded, imaging follows, usually with a gallium-68 DOTATATE PET/CT to find the tumor and assess the extent of disease. Multiphasic CT or MRI fills in the anatomical detail and helps plan surgery or other interventions. A biopsy confirms the diagnosis and provides grading information. If there is concern about heart involvement, echocardiography and NT-proBNP round out the picture.

One thing that catches people off guard is how many of these tests require preparation. You need to restrict certain foods and medications before 5-HIAA testing, stop PPIs before chromogranin A testing, and sometimes fast before imaging. Ask your medical team for written prep instructions ahead of each test, because getting it wrong usually means repeating it, which delays diagnosis and adds frustration. The testing process can feel drawn out, but each layer adds information that shapes the treatment plan. A confident diagnosis rests on the convergence of biochemistry, imaging, and pathology, and cutting corners on any one of them risks misclassification or missed disease.